Skip to main content
. 2015 Mar 8;6(8):5615–5633. doi: 10.18632/oncotarget.3479

Figure 1. Expression and prognostic significance of CD5 in de novo DLBCL.

Figure 1

(A-B) Representative of CD5+ and CD5− immunohistochemical staining; (C) Distribution and comparison of CD5 expression between GCB- and ABC-DLBCL; (D-I) CD5 expression was correlated with significantly poor OS and PFS in the overall, GCB-, and ABC- DLBCL cohorts; (J-K) Bone marrow involvement was correlated with significantly poorer OS and PFS in patients with CD5+ DLBCL; (L) Expression of CXCR4 in CD5+ and CD5− GCB- or ABC-DLBCL patients.